RallyBio Avenzo merger aims to strengthen rare disease pipeline after a previous attempt with Candid Therapeutics fell through.
Browsing: M&A and Licensing
News and insights on mergers, acquisitions, licensing deals, and strategic collaborations across the global pharma industry.
Servier Edgewise acquisition involves a muscular dystrophy tablet with potential peak sales exceeding $2 billion.
Lilly vaccine acquisitions include Curevo, LimmaTech, and Vaccine Co., totaling $4 billion, to enhance its infectious disease portfolio.
Sun Pharma acquisition highlights India’s global ambitions, but infrastructure and policy gaps remain challenges.
Assertio buyout bid accepted, offering a 31% premium over initial proposal, impacting the US market.
Arvinas Pfizer Rigel deal secures future of Veppanu, a novel breast cancer drug, ending months of uncertainty.
Bristol Myers Hengrui alliance involves 13 drugs, marking a significant step in global pharmaceutical collaboration.
Lilly Gilead M&A activity is driving pharma’s 2026 boom, with a focus on cancer and autoimmune drugs.
Angelini Catalyst acquisition enhances CNS drug portfolio and U.S. market access, valued at $4 billion.
Roche PathAI acquisition aims to improve cancer diagnosis with advanced digital pathology tools.